| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
3.35 -0.04 (-0.01%) |
06-19 16:00 |
|
Open: |
3.37 |
Pre close: |
3.39 |
Target:
|
4.38 
|
|
High: |
3.381 |
Low: |
3.3 |
Resistance:
|
3.75
4.05
|
|
Volume: |
101,977 |
Market Cap: |
215M |
Support:
|
3.27
2.72
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
3.40
|
MACD |
MACD(12,26):
|
-0.13 |
|
MA(20): |
3.54 |
Signal(12,26,9): |
-0.13 |
|
MA(100): |
3.74  |
Stochastic Oscillator |
%K(14,3):
|
20.75 |
|
MA(250): |
3.71 |
%D(3): |
24.79 |
|
Average Volume(K) |
3-Month: |
11006
|
52-Week |
High:
|
4.69 |
|
10-Days: |
11398 |
Low: |
3.00 |
|
RSI |
RSI(14):
|
33.24 |
Change(%): |
-10.9 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
1107.9 |
Shares Out. (M) |
57.84 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-906.6 |
Shares Float (M) |
54.67 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
94.9 |
% Held by Institutions |
5.60 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
1368 |
|
Book Value (p.s.) |
27420.811 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.00 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.30 |
P/S |
0.00 |
|
Operating Margin |
-4406.38 |
Levered Free Cash Flow
(M) |
-2.35 |
P/CF |
-26.54 |
|
|
|
|
|
|
